CY2236B1 - Dry mix formulation for bisphosphonic acids - Google Patents

Dry mix formulation for bisphosphonic acids

Info

Publication number
CY2236B1
CY2236B1 CY0100005A CY0100005A CY2236B1 CY 2236 B1 CY2236 B1 CY 2236B1 CY 0100005 A CY0100005 A CY 0100005A CY 0100005 A CY0100005 A CY 0100005A CY 2236 B1 CY2236 B1 CY 2236B1
Authority
CY
Cyprus
Prior art keywords
bisphosphonic acid
stearate
amino
lactose
hydroxybutylidene
Prior art date
Application number
CY0100005A
Other languages
English (en)
Inventor
Simon R Bechard
Kenneth A Kramer
Ashok V Katdare
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25530524&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2236(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY2236B1 publication Critical patent/CY2236B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0100005A 1992-12-02 2001-04-04 Dry mix formulation for bisphosphonic acids CY2236B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/984,399 US5358941A (en) 1992-12-02 1992-12-02 Dry mix formulation for bisphosphonic acids with lactose

Publications (1)

Publication Number Publication Date
CY2236B1 true CY2236B1 (en) 2003-07-04

Family

ID=25530524

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0100005A CY2236B1 (en) 1992-12-02 2001-04-04 Dry mix formulation for bisphosphonic acids

Country Status (32)

Country Link
US (5) US5358941A (pt)
EP (2) EP0690719B1 (pt)
JP (3) JP3365634B2 (pt)
KR (2) KR100286063B1 (pt)
CN (3) CN1066624C (pt)
AT (1) ATE196736T1 (pt)
AU (1) AU677264C (pt)
BG (1) BG62795B1 (pt)
CA (1) CA2149052C (pt)
CY (1) CY2236B1 (pt)
CZ (2) CZ289966B6 (pt)
DE (1) DE69329533T2 (pt)
DK (1) DK0690719T3 (pt)
ES (1) ES2150979T3 (pt)
FI (1) FI113839B (pt)
GR (1) GR3034936T3 (pt)
HK (1) HK1009252A1 (pt)
HU (1) HU220604B1 (pt)
IL (1) IL107741A (pt)
LV (1) LV12715B (pt)
MX (1) MX9307569A (pt)
NO (1) NO308986B1 (pt)
NZ (1) NZ258442A (pt)
PL (1) PL309245A1 (pt)
PT (1) PT690719E (pt)
RO (1) RO113429B1 (pt)
RU (1) RU2148405C1 (pt)
SK (1) SK282100B6 (pt)
TW (1) TW422707B (pt)
UA (1) UA46701C2 (pt)
WO (1) WO1994012200A1 (pt)
ZA (1) ZA938979B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US6096342A (en) 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB2295966B (en) * 1994-12-14 1997-09-24 Bioglan Ireland Direct compression tablets
AU713824B2 (en) * 1995-05-12 1999-12-09 Merck Sharp & Dohme Corp. Prevention of tooth loss by the administration of alendronate or its salts
WO1996039410A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
JP3344726B2 (ja) * 1995-06-06 2002-11-18 メルク エンド カンパニー インコーポレーテッド 無水アレンドロネート一ナトリウム塩製剤
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
BR9712197A (pt) * 1996-10-04 1999-08-31 Merck & Co Inc Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
IL121623A (en) 1997-08-26 2000-06-29 Unipharm Ltd Process for the preparation of solid oral dosage forms comprising alendronic acid
US7598246B2 (en) 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
BR9910481A (pt) 1998-06-11 2001-01-09 Upjohn Co Composição farmacêutica para comprimido de liberação não-contìnua
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
CZ20002567A3 (cs) 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
WO2002055009A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
EP1377276B1 (en) * 2001-04-10 2011-10-05 Sun Pharma Advanced Research Company Limited Timed pulse release composition
EA005949B1 (ru) * 2001-05-01 2005-08-25 Пфайзер Продактс Инк. Способ производства фармацевтической композиции низкой дозы
ES2268086T3 (es) * 2001-05-02 2007-03-16 Novartis Ag Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
JP2005522526A (ja) * 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
CN1665825A (zh) * 2002-05-17 2005-09-07 特瓦制药工业有限公司 用一定的稀释剂制备双膦酸
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
NZ546349A (en) * 2003-09-29 2010-03-26 Cipla Ltd Pharmaceutical formulation with improved stability
US6783772B1 (en) * 2003-12-12 2004-08-31 Sanjeev Khandelwal Pharmaceutical preparations containing alendronate sodium
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US8158153B2 (en) * 2005-03-17 2012-04-17 Alkermes Pharma Ireland Limited Nanoparticulate bisphosphonate compositions
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
WO2008020305A2 (en) * 2006-08-17 2008-02-21 Aurobindo Pharma Limited Solid dosage forms of bisphosphonic acids
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
CA2658834A1 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Bisphosphonate inhalant formulations and methods for using the same
WO2008074144A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
LT2391355T (lt) 2009-05-19 2017-03-10 Celgene Corporation 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diono kompozicijos
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9717720B2 (en) 2011-02-10 2017-08-01 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
RU2640582C2 (ru) 2011-08-01 2018-01-10 Мбс Фарма, Инк. Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
KR20210033073A (ko) * 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3182996B1 (en) 2014-08-22 2022-12-28 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CN105380949A (zh) 2014-09-02 2016-03-09 健脂生物科技股份有限公司 治疗高脂肪食品诱发肝脏脂肪蓄积的组合物
CN107334770A (zh) 2016-05-02 2017-11-10 健脂生物科技股份有限公司 治疗脂质代谢紊乱的组合物及其方法
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1036368A (en) * 1963-10-31 1966-07-20 Nat Dairy Prod Corp Method for the manufacture of lactose-containing tablets
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
EP0275468B1 (de) * 1986-12-20 1991-02-06 Roche Diagnostics GmbH Clodronat-haltige Arzneimittel und Verfahren zur Herstellung derselben
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US5070108A (en) * 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose

Also Published As

Publication number Publication date
JP3365634B2 (ja) 2003-01-14
RU2148405C1 (ru) 2000-05-10
EP1051975A1 (en) 2000-11-15
FI113839B (fi) 2004-06-30
NO308986B3 (no) 2000-11-27
JPH08506092A (ja) 1996-07-02
DK0690719T3 (da) 2000-12-18
HUT72645A (en) 1996-05-28
CN1554349A (zh) 2004-12-15
AU5611594A (en) 1994-06-22
RO113429B1 (ro) 1998-07-30
SK73195A3 (en) 1995-12-06
LV12715B (en) 2001-12-20
ATE196736T1 (de) 2000-10-15
NZ258442A (en) 1996-12-20
HU9501590D0 (en) 1995-08-28
CA2149052C (en) 2003-03-25
US5882656A (en) 1999-03-16
US5681590A (en) 1997-10-28
KR100473750B1 (ko) 2005-03-07
EP0690719A1 (en) 1996-01-10
NO952184D0 (no) 1995-06-01
PT690719E (pt) 2001-02-28
BG99663A (bg) 1996-02-28
CN1098907A (zh) 1995-02-22
IL107741A0 (en) 1994-02-27
CZ289966B6 (cs) 2002-05-15
US6194004B1 (en) 2001-02-27
KR950703985A (ko) 1995-11-17
KR20030096426A (ko) 2003-12-31
FI952685A0 (fi) 1995-06-01
DE69329533D1 (de) 2000-11-09
WO1994012200A1 (en) 1994-06-09
KR100286063B1 (ko) 2001-05-02
CA2149052A1 (en) 1994-06-09
IL107741A (en) 1997-06-10
HK1009252A1 (en) 1999-05-28
US6090410A (en) 2000-07-18
BG62795B1 (bg) 2000-08-31
UA46701C2 (uk) 2002-06-17
NO952184L (no) 1995-06-01
CZ134695A3 (en) 1995-10-18
CN1066624C (zh) 2001-06-06
HU220604B1 (hu) 2002-03-28
AU677264B2 (en) 1997-04-17
SK282100B6 (sk) 2001-11-06
DE69329533T2 (de) 2001-05-31
AU677264C (en) 2005-09-29
JP4267877B2 (ja) 2009-05-27
EP0690719B1 (en) 2000-10-04
ES2150979T3 (es) 2000-12-16
EP0690719A4 (pt) 1996-01-24
US5358941A (en) 1994-10-25
TW422707B (en) 2001-02-21
CN1233468A (zh) 1999-11-03
MX9307569A (es) 1995-01-31
JP2003073277A (ja) 2003-03-12
FI952685A (fi) 1995-06-01
JP2002348241A (ja) 2002-12-04
CZ290197B6 (cs) 2002-06-12
GR3034936T3 (en) 2001-02-28
ZA938979B (en) 1994-08-03
JP3854187B2 (ja) 2006-12-06
CN1160076C (zh) 2004-08-04
LV12715A (lv) 2001-09-20
NO308986B1 (no) 2000-11-27
PL309245A1 (en) 1995-10-02

Similar Documents

Publication Publication Date Title
ZA938979B (en) Dry mix formulation for bisphosphonic acids
WO1996014365A3 (en) Process for stabilizing gelatin products
HUT50631A (en) Process for producing long-acting pharmaceutical compositions comprising etodolac active ingredient
CA2301185A1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
EP0454396A1 (en) Tablet composition and method for problem pharmaceutical materials
KR920002155A (ko) 슈크랄페이트(Sucralfate) 저작성 타블렛
CA2008509A1 (en) Stabilizing System for Solid Dosage Forms
SI8710406B (sl) Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
CA2136071A1 (en) 2-arylpropionic acid compositions and process for preparing the same
GB1473315A (en) Freeze-dried flavoured pharmaceuticals
CA2199155A1 (en) Process for stabilizing gelatin products